The efficacy of tyrosine kinase inhibitors erlotinib and gefitinib in the treatment of EGFR-mutated lung adenocarcinomas was a further boost for the concept of targeted therapy [4, 5] and forced pathology departments to implement EGFR mutation testing. Here, EGFR is linked to lung adenocarcinoma.